After hours, Sarepta surged over 33%! Its DMD gene therapy Elevidys approved for expanded indications
I'm PortAI, I can summarize articles.
The U.S. Food and Drug Administration (FDA) has approved the expansion of indications for the gene therapy Elevidys, developed jointly by Sarepta and Roche, to include Duchenne muscular dystrophy (DMD) patients aged at least 4 years old. Sarepta's stock price surged more than 33% after hours. Elevidys is a recombinant gene therapy that can provide clinical benefits to non-ambulatory DMD patients. Sarepta will conduct randomized controlled trials to validate and confirm the clinical effects of Elevidys in patients
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments